(CercleFinance.com) – GSK announced on Monday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing of daprodustat for the treatment of anemia linked to chronic kidney disease.
The company specifies that the favorable opinion of the advisory committee of the European Medicines Agency (EMA) concerning this oral hypoxia-induced factor prolyl-hydroxylase inhibitor (HIF-PHI) concerns dialysis patients.
Daprodustat has already received marketing approval for the treatment of patients with renal anemia in the United States, as well as in Japan, under the trade name Duvroq.
According to GSK, more than 700 million people currently suffer from chronic kidney disease worldwide, with one in seven patients showing signs of anemia.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
This is a Smartvoice article: see legal notice